摘要
目的:探讨银杏内酯注射液联合依达拉奉右崁醇对急性脑梗死(ACI)患者缺血再灌注损伤及炎症因子的影响。方法:选取2022年1月至2024年4月河南大学第一附属医院急诊科收治的187例ACI患者随机分为依达拉奉右崁醇组(A组)65例,银杏内酯注射液组(B组)60例,联合组62例。A组采取常规静脉溶栓+依达拉奉右崁醇治疗,B组采取常规静脉溶栓+银杏内酯注射液治疗,联合组采取常规静脉溶栓+依达拉奉右崁醇+银杏内酯治疗,均治疗2周。观察3组患者的临床效果,治疗前和治疗2周后Barthel指数(BI)量表和NIHSS评分、脑血流动力学指标[平均血流速度(Vm)、收缩期峰值血流速度(Vs)、舒张末期血流速度(Vd)]、神经功能指标[N末端脑钠肽前体(NT-proBNP)、脑源性神经营养因子(BDNF)、神经元特异性烯醇化酶(NSE)]和炎症因子水平[白细胞介素-12(IL-12)、超敏C反应蛋白(hs-CRP)、干扰素(IFN)-y]以及统计不良反应。结果:治疗2周后,A组、B组的总有效率低于联合组(P<0.05);治疗2周后,联合组Vm、Vs、Vd水平、BI量表评分、BDNF的含量均高于A组、B组(P<0.05);治疗2周后,联合组NIHSS评分、NT-proBNP、NSE、IL-12、hs-CRP、IFN-γ水平均低于A组、B组(P<0.05);治疗期间3组患者不良反应无明显差异(P>0.05)。结论:银杏内酯注射液与依达拉奉右崁醇联用,可明显改善ACI患者的临床治疗效果,有效保护患者脑功能并抑制机体缺血-再灌注损伤,减轻神经功能损伤,降低机体炎症水平,且安全性较好。
Objective:To investigate the effects of Ginkgolide injection combined with edaravone dexborneol on ischemia-reperfusion injury and inflammatory factors in patients with acute cerebral infarction(ACI).Methods:187 ACI patients admitted to the emergency department of the irst Affiliated Hospital of Henan University from January 2022 to April 2024 were randomly divided into three groups:edaravone dexborneol group(Group A,n=65),Ginkgolide injection group(Group B,n=60)and combination group(n=62).Group A received conventional intravenous thrombolysis plus edaravone dexborneol,Group B received conventional intravenous thrombolysis plus Ginkgolide injection,and the combination group received conventional intravenous thrombolysis plus edaravone dexborneol and Ginkgolide injection.All groups were treated for 2 weeks.Clinical efficacy was observed,and Barthel Index(BI)scores,NIHSS scores,cerebral hemodynamic parameters[mean blood flow velocity(Vm),systolic peak blood flow velocity(Vs),diastolic blood flow velocity(Vd)],neurological indicators[N-terminal pro-brain natriuretic peptide(NT-proBNP),brain-derived neurotrophic factor(BDNF),neuron-specific enolase(NSE)]and inflammatory factor levels[interleukin-12(IL-12),high-sensitivity C-reactive protein(hs-CRP),interferon(IFN)-γ]were measured before and 2 weeks after treatment.Adverse reactions were also recorded.Results:After 2 weeks of treatment,the total effective rates in Groups A and B were lower than those in the combination group(P<0.05).The combination group showed higher Vm,Vs,Vd levels,BI scores and BDNF levels compared to Groups A and B(P<0.05).Meanwhile,NIHSS scores,NT-proBNP,NSE,IL-12,hs-CRP and IFN-γlevels were lower in the combination group than in Groups A and B(P<0.05).No significant differences in adverse reactions were observed among the three groups during treatment(P>0.05).Conclusion:The combination of Ginkgolide injection and edaravone dexborneol significantly improves clinical outcomes in ACI patients,effectively protects cerebral function,inhibits ischemia-reperfusion injury,reduces neurological damage,lowers inflammatory levels,and demonstrates good safety.
作者
刘力源
杨妍妍
李晓晖
LIU Liyuan;YANG Yanyan;LI Xiaohui(Department of Emergency,The First Affiliated Hospital of Henan University,Kaifeng 475000,China)
出处
《黑龙江医药科学》
2025年第6期73-77,共5页
Heilongjiang Medicine and Pharmacy
基金
开封市科技发展计划项目,编号:2303020。
关键词
银杏内酯注射液
依达拉奉右崁醇
急性脑梗死
缺血再灌注损伤
炎症因子
Ginkgolide injection
Edaravone Dexborneol
acute cerebral infarction
ischemia-reperfusion injury
inflammatory factors
作者简介
刘力源(1991-),男,河南周口人,硕士,住院医师;通信作者:李晓晖(1977-),男,河南开封人,硕士,副主任医师。E-mail:lixh1977@126.com。
